Cyclosporine and skin allografts for the treatment of thermal injury. II. Development of an experimental massive third-degree burn model demonstrating extensive graft survival.
We have previously reported the successful treatment and apparent development of skin allograft tolerance in a patient sustaining massive burns, utilizing skin allografts and cyclosporine. We now report the experimental correlate via successful achievement of a 75% body surface area (BSA) scald burn cyclosporine-skin allograft model in Lewis (LEW) rats. Cyclosporine (8 mg/kg/day) was given to the experimental animals daily for the first 20 days and then three times a week thereafter. Two experimental groups were studied: one received standard posttrauma care and the second critical posttrauma care. Controls (n = 22) and experimental groups 1 (n = 28) and 2 (n = 4) had average survival times of 13.8 +/- 12.8 days, 44.2 +/- 132.5 days, and 172.0 +/- 19.4 days, respectively. The allografts on the surviving experimental animals appeared normal and healthy and had nearly perfect hair growth. These results indicate that the model follows the clinical burn wound course, and treatment of massive burns with primary excision, skin allografts, and low doses of cyclosporine could provide immediate and complete functional repair of the burn wound.
Black
K S
KS
Reconstructive Microsurgery Laboratory, University of California, Irvine 92717.
Hewitt
C W
CW
Smelser
S
S
Yearsley
S
S
Bazzo
D E
DE
Achauer
B M
BM
D000818:Animals; D002056:Burns / Q000473:pathology / Q000628:therapy*; D003524:Cyclosporins / Q000627:therapeutic use*; D003646:Debridement; D006085:Graft Survival; D009336:Necrosis; D051381:Rats; D011914:Rats, Inbred BN / Q000276:immunology; D011917:Rats, Inbred Lew / Q000276:immunology; D012867:Skin / Q000473:pathology; D016038:Skin Transplantation; D014184:Transplantation, Homologous
D003524:Cyclosporins